Posted on August 20th, 2014
Mr. Elam currently serves as AntriaBio's Chairman and CEO.
Company OverviewAntriaBio, Inc.’s (OTCQB: ANTB) lead diabetes product candidate, AB101, is a once-a-week injectable basal insulin that is currently in preclinical development. AB101 is administered by subcutaneous injection and targets patients with type 1 and type 2 diabetes who require basal insulin for the control of hyperglycemia. The formulation has been designed to release insulin slowly and uniformly over a period of approximately one week without an adverse initial burst of insulin. The release profile results in a low and sustained insulin level which supplements the effects of endogenous and exogenous insulin and complements the effects of orally administered hypoglycemic agents. AB101 has the potential to be a clearly differentiated product that represents a significant advance in basal insulin delivery. AB101’s long duration of action is the result of our ability to PEGylate insulin and then encapsulate it ... Learn More »
I was thrilled to see MannKind and Sanofi’s announcement regarding their licensing agreement to bring Afrezza to marke...Read More »
Posted on August 10th, 2014
On Friday, August 8th, 2014, we filed a preliminary proxy statement with the United States Securities and Exchange Commi...Read More »
Posted on August 6th, 2014
Dear Readers, Welcome to the inaugural Matinas BioPharma CEO Blog! I am very excited to share some of our learning’...Read More »
Reveal Insights About Your Company and Industry to Shareholders.
We are an exclusive, online media publication where public and privatively held firms alike share insights about their companies and industries...Learn More »